Management claims purchase orders for the entirety of next year while custom silicon revenue dropped sequentially this quarter.
Thesis: Marvell is a derivative play on hyperscaler CapEx priced as a primary beneficiary. They are buying growth (Celestial) to backfill organic lumpiness in custom silicon. The bull case requires believing a 40% growth ramp in FY28 based on 'visibility' three years out. The structural position is weaker than the guidance suggests: they are squeezed between TSMC's pricing power and hyperscaler concentration. The 'base case' leaves zero room for error.
Verdict: AVOID — Conviction: MEDIUM
Catalyst: Fiscal 2027 Q1 earnings will confirm if the 'custom silicon rebound' is real or if the sequential decline was a leading indicator of saturation.
Key Risk: Hyperscaler CapEx deceleration in calendar 2026 would shatter the FY28 'base case' of 40% growth, which assumes sustained 20%+ market expansion.
The Tell: After asserting they have purchase orders for the 'entirety of next fiscal year', CEO Murphy immediately undercut it: 'I am also mindful of some of the history on this custom business where either people got ahead of themselves or there's a lot of noise.' He knows the orders are cancellable or the timing is fluid.
Friction Level: MODERATE_FRICTION — Credibility of the 'no air pockets' custom silicon guidance against a history of cyclical volatility.
Report not found
The report data is no longer available. Please return to the archive.